Significant Influence of Abemaciclib on Rivaroxaban.

IF 2.8 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Therapeutic Drug Monitoring Pub Date : 2025-02-14 DOI:10.1097/FTD.0000000000001301

Xiaoshuang He, Yongjie Ding, Jie Fang, Juntao Zhao, Xiaoli Ma, Fengmei Hu, Qing Qu, Xiaolan Bian, Qiuya Lu

引用次数: 0

Abstract

Background: A patient was treated with abemaciclib and rivaroxaban. Therapeutic drug monitoring revealed high total plasma concentrations of rivaroxaban, which was identified as likely cause of abnormal bleeding. This result indicating that it was caused by drug-drug interaction.

Methods: According to the pharmacokinetic profile, the concentrations of rivaroxaban, abemaciclib, and its metabolite (M2) were monitored.

Results: The concentrations of abemaciclib and its metabolite (M2) decreased with the reduction in rivaroxaban dosage.

Conclusions: This case study demonstrates the interactions between abemaciclib and rivaroxaban. For patients with complex medications, therapeutic drug monitoring can reduce the occurrence of adverse effects.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Drug Monitoring 医学-毒理学

CiteScore

5.00

自引率

8.00%

发文量

213

审稿时长

4-8 weeks

期刊介绍： Therapeutic Drug Monitoring is a peer-reviewed, multidisciplinary journal directed to an audience of pharmacologists, clinical chemists, laboratorians, pharmacists, drug researchers and toxicologists. It fosters the exchange of knowledge among the various disciplines–clinical pharmacology, pathology, toxicology, analytical chemistry–that share a common interest in Therapeutic Drug Monitoring. The journal presents studies detailing the various factors that affect the rate and extent drugs are absorbed, metabolized, and excreted. Regular features include review articles on specific classes of drugs, original articles, case reports, technical notes, and continuing education articles.